ClinicalTrials.Veeva

Menu

PLATFORM to Maximize Patient Knowledge of Health Goals After Acute Myocardial Infarction

Duke University logo

Duke University

Status

Completed

Conditions

Acute Myocardial Infarction

Treatments

Other: Educational Tool

Study type

Interventional

Funder types

Other
Other U.S. Federal agency
Industry

Identifiers

NCT01807208
Pro00034650
5U19HS021092 (U.S. AHRQ Grant/Contract)

Details and patient eligibility

About

The goals of this study are two fold: 1) To learn whether a personalized patient health goal and reminder tool helps patients to learn more about their condition and to make changes in behavior and medication taking to reduce the risk of another heart attack. 2) To examine a blood sample to learn how patients are responding to their medications. The study team will enroll approximately 220 patients in the hospital recovering from a heart attack. Half of the patients will receive the educational tools and a copy will be sent to their outpatient provider.

Full description

The goals of this study are two fold: 1) To evaluate the impact of a personalized patient health goal education and reminder tool on patient adherence to evidence based therapies and subsequent cardiovascular risk factor modification after acute myocardial infarction (AMI); 2) To assess age-related heterogeneity in antiplatelet response among AMI patients. This is a prospective study of ~220 AMI patients, with at least half over age 65 years. Patients will be surveyed with questionnaires (at baseline and 6 months post discharge) and biomarkers (baseline only) to assess the status of their physical function, depression, nutrition, inflammation, and response to antiplatelet therapies. Patients will also be administered a walking test and a grip strength test at baseline. About 1 week after hospital discharge, and again about 3 months after hospital discharge, about half of the patients and their outpatient providers will receive the personalized post-AMI health goal education and reminder tool on patient adherence to evidence-based secondary prevention therapies. Data will be analyzed in aggregate using descriptive statistics. The primary endpoint of interest is a composite measure of adherence at six months to secondary prevention therapies described as the sum of measures received divided by the sum of available opportunities. The secondary endpoint will be analyzed to describe platelet response profiles as a function of age. The study team anticipates the risks for this study to be minimal, since the patient does not receive any investigational therapies.

Enrollment

192 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patients with either ST-elevation MI (STEMI) or non-ST-elevation MI (NSTEMI) who are on antiplatelet therapy at the time of enrollment.
  2. English language literacy and
  3. Able to provide written informed consent.

Exclusion criteria

  1. Patients less than 18 years of age.
  2. Patients who are unable or unwilling to comply with the protocol or not expected to complete the study period, including its follow-up requirements
  3. Life expectancy less than 6 months or discharged on hospice care.
  4. Patients without at least 1 scheduled outpatient follow-up visit inside the Duke University Affiliated Physicians network.
  5. Patients who receive a coronary artery bypass grafting (CABG) during the eligible enrollment hospitalization.
  6. Active chronic inflammatory conditions (e.g., inflammatory bowel disease, lupus, rheumatoid arthritis)

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

192 participants in 2 patient groups

Educational tool
Experimental group
Description:
Patients randomized to the educational tool arm of the study will receive mailed educational materials at 1 week post hospital discharge and again at 3 months after discharge.
Treatment:
Other: Educational Tool
Usual care
No Intervention group
Description:
Patients in this arm of the study will receive usual care.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems